Corcept Therapeutics Incorporated
CORT
$33.33
$0.030.09%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.12% | 13.75% | 18.70% | 7.09% | 34.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.12% | 13.75% | 18.70% | 7.09% | 34.33% |
| Cost of Revenue | -13.90% | 60.31% | 36.01% | 18.08% | 57.49% |
| Gross Profit | 11.54% | 13.00% | 18.43% | 6.93% | 34.00% |
| SG&A Expenses | 56.21% | 68.12% | 55.15% | 61.12% | 76.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.18% | 45.22% | 30.85% | 31.67% | 50.99% |
| Operating Income | -82.24% | -78.07% | -25.05% | -88.61% | -20.23% |
| Income Before Tax | -68.99% | -71.21% | -23.81% | -72.51% | -13.17% |
| Income Tax Expenses | -1,284.35% | -177.23% | -156.60% | -251.14% | -77.74% |
| Earnings from Continuing Operations | -21.00% | -58.34% | -0.96% | -25.99% | -1.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.00% | -58.34% | -0.96% | -25.99% | -1.94% |
| EBIT | -82.24% | -78.07% | -25.05% | -88.61% | -20.23% |
| EBITDA | -81.30% | -77.60% | -24.41% | -87.71% | -19.89% |
| EPS Basic | -21.38% | -58.60% | -2.41% | -27.19% | -3.55% |
| Normalized Basic EPS | -69.02% | -71.26% | -24.51% | -73.26% | -14.16% |
| EPS Diluted | -21.54% | -60.98% | -9.38% | -32.00% | -8.92% |
| Normalized Diluted EPS | -69.34% | -72.58% | -29.65% | -75.12% | -18.75% |
| Average Basic Shares Outstanding | 0.05% | 0.17% | 0.96% | 1.28% | 1.16% |
| Average Diluted Shares Outstanding | 1.18% | 5.03% | 8.31% | 9.01% | 6.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |